Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068663 | 0.83 | CA12 (0.52) | MAOACA12CA1CA9CYP3A4 | |
| SCHEMBL7070719 | 0.77 | CA12 (0.46) | MAOACA12CA1CA9CYP3A4 | |
| SCHEMBL30668699 | 0.77 | KDM4E (0.61) | MAOAKDM4EALDH1A1NPC1LMNA | |
| Xanthone SCHEMBL5694514 | 0.74 | MAOA (0.62) | MAOACA12CA1CA9CYP3A4 | |
| SCHEMBL7128865 | 0.74 | CA12 (0.50) | MAOACA12CA1CA9CYP3A4 | |
| SCHEMBL133401 | 0.72 | MAOA (0.57) | MAOACYP3A4KDM4EALDH1A1NPC1 | |
| SCHEMBL30668674 | 0.72 | MAOA (1.00) | MAOACYP3A4KDM4EALDH1A1NPC1 | |
| SCHEMBL29393962 | 0.72 | CA12 (1.00) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL8515316 | 0.72 | CA12 (1.00) | CA12CA1CA9CYP3A4CYP2A6 | |
| SCHEMBL132462 | 0.72 | MAOA (1.00) | MAOACYP3A4KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-06-03 | — | — | US | disclosed |
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-06-03 | — | — | US | disclosed |
| US-7592143-B2 | Methods of treating diseases responsive to induction of apoptosis and screening assays | CYTOVIA, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008057604-A9 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | UNIV CALIFORNIA (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008057604-A9 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | UNIV CALIFORNIA (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008057604-A2 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057604-A2 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1620564-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1620564-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | CYTOVIA, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004094647-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | BAD, CASP3, BID | MAOA 3590/4885CA12 2416/4885CA1 2498/4885 |
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | HEATR6, HEATR1, AIP | MAOA 4083/4885CA12 3020/4885CA1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.